Dravet syndrome

What is Dravet syndrome?

Dravet syndrome, also known as severe myoclonic epilepsy of infancy, is a rare and severe form of epilepsy that begins in the first year of life. This devastating neurological condition affects approximately 1 in 15,700 children and is characterized by prolonged seizures triggered by fever, multiple seizure types, and significant developmental delays. Most cases are caused by mutations in the SCN1A gene that occur spontaneously (de novo), meaning they are not inherited from parents but arise as new genetic changes during early development.

Key statistics

Symptoms

Primary symptoms: Prolonged febrile seizures, myoclonic seizures, focal seizures, generalized tonic-clonic seizures, developmental delay, intellectual disability, movement disorders, behavioral problems.

The journey of Dravet syndrome typically begins with prolonged seizures triggered by fever during infancy, often lasting more than 30 minutes. These initial seizures may alternate between the left and right sides of the body. As children develop, multiple seizure types emerge, including myoclonic seizures (sudden muscle jerks), focal seizures affecting one part of the brain, and generalized tonic-clonic seizures.

Beyond seizures, children experience significant developmental delays that become apparent in the second year of life. Speech and language development is particularly affected, with many children remaining nonverbal or having severely limited communication abilities. Motor development is also impaired, leading to difficulties with walking, coordination, and fine motor skills. Behavioral challenges are common, including hyperactivity, attention deficits, autism spectrum behaviors, and sleep disturbances. Many children develop a characteristic crouched gait and may experience frequent falls due to balance problems.

Submit Your Paper

Causes and risk factors

Dravet syndrome is primarily caused by mutations in the SCN1A gene, which provides instructions for making a sodium channel protein essential for proper nerve cell function in the brain. Approximately 85% of individuals with Dravet syndrome have identifiable SCN1A mutations. The remaining 15% may have mutations in other genes such as SCN1B, SCN2A, or GABRG2, or the genetic cause may remain unknown.

The vast majority of cases (over 95%) occur as de novo mutations, meaning they are spontaneous genetic changes that occur during early development and are not inherited from either parent. This means that parents of affected children typically have no family history of the condition and no increased risk factors. The mutation rate appears to be random, with no known environmental or lifestyle factors that increase the risk of having a child with Dravet syndrome.

Prevention

There is currently no way to prevent Dravet syndrome, as it results from spontaneous genetic mutations that occur during early development. Since most cases are de novo mutations, standard genetic counseling and carrier testing do not apply to most families. However, in the rare instances where a parent has a mosaic SCN1A mutation, genetic counseling and preimplantation genetic testing may be considered for future pregnancies.

For families with an affected child, genetic testing can confirm the diagnosis and inform family planning decisions. While the recurrence risk is generally low (less than 5%) for de novo mutations, genetic counseling is recommended to discuss individual risks and reproductive options.

Complications

Without proper treatment, Dravet syndrome can lead to severe and life-threatening complications. Status epilepticus, prolonged seizures lasting more than 30 minutes, is common and can cause brain damage or death if not treated promptly. The most serious complication is sudden unexpected death in epilepsy (SUDEP), which affects 15-20% of individuals with Dravet syndrome by adulthood.

Progressive intellectual disability is universal, with most individuals functioning in the severe to profound range. Communication remains severely impaired, with many never developing functional speech. Mobility issues worsen over time, and many individuals eventually require wheelchair assistance. Behavioral challenges can become severe, including aggression and self-injurious behaviors that significantly impact family functioning and care options.

Diagnosis

Diagnosis of Dravet syndrome is based on clinical criteria combined with genetic testing. The diagnostic journey often begins with the characteristic presentation of prolonged febrile seizures in infancy, followed by the development of multiple seizure types and developmental regression in the second year of life.

Electroencephalography (EEG) may initially appear normal but typically shows generalized spike-wave discharges and focal abnormalities as the condition progresses. Brain magnetic resonance imaging (MRI) is usually normal in early stages but may show mild brain atrophy in later stages. The definitive diagnosis is confirmed through genetic testing for SCN1A mutations using DNA sequencing and deletion/duplication analysis.

Additional testing may include metabolic screens to rule out other causes of epilepsy, and comprehensive epilepsy gene panels may be considered if SCN1A testing is negative. The diagnostic process can be lengthy and emotionally challenging for families, often taking months to years before reaching a definitive diagnosis.

Treatment

Treatment of Dravet syndrome focuses on seizure control and supportive care, though seizures often remain difficult to control despite multiple medications. Several medications have shown specific efficacy for Dravet syndrome and are considered first-line treatments.

Stiripentol is often used in combination with valproate and clobazam as a first-line treatment regimen. Cannabidiol (pharmaceutical-grade CBD) has shown significant efficacy in reducing seizure frequency and is approved specifically for Dravet syndrome. Fenfluramine is another recently approved orphan drug that has demonstrated effectiveness in clinical trials.

Other antiepileptic drugs that may be beneficial include valproate, clobazam, levetiracetam, and topiramate. Importantly, certain medications should be avoided as they can worsen seizures in Dravet syndrome, including sodium channel blockers like lamotrigine, carbamazepine, and phenytoin.

Non-pharmacological treatments include ketogenic diet therapy, which has shown benefits in some patients. Supportive therapies are crucial and include physical therapy, occupational therapy, speech therapy, and behavioral interventions. Emergency medications such as rectal diazepam or intranasal midazolam are prescribed for prolonged seizures.

Prognosis

The prognosis for Dravet syndrome remains challenging, with most individuals experiencing lifelong seizures and severe intellectual disability. While modern treatments have improved seizure control and quality of life, the condition typically progresses to severe disability requiring lifelong care.

Life expectancy is reduced, with a mortality rate of 15-20% by adulthood, primarily due to SUDEP, status epilepticus, and accidents related to seizures. However, with optimal treatment and care, many individuals can live into their adult years. Early diagnosis and appropriate treatment can slow the progression of cognitive decline and improve overall quality of life.

The degree of intellectual disability varies, but most individuals function in the severe to profound range. Independence in activities of daily living is rare, and most individuals require full-time care throughout their lives.

Quality of life

Living with Dravet syndrome requires comprehensive daily management and family adaptation. Establishing consistent routines is crucial, as stress and disruption can trigger seizures. Temperature regulation is important since fever can precipitate seizures, requiring careful monitoring and prompt treatment of illnesses.

Sleep management is essential, as sleep deprivation can increase seizure frequency. Many families find that maintaining consistent sleep schedules and creating calm bedtime routines helps reduce nighttime seizures. Diet modifications, particularly ketogenic diets, may be recommended and require careful monitoring by healthcare teams.

Physical activity should be encouraged within safe limits, though activities involving water, heights, or potential head trauma require careful supervision. Many families adapt their homes with safety modifications including seizure monitors, padded surfaces, and emergency medication accessibility.

Mental health support is crucial for both patients and families. Connecting with other families through patient organizations provides invaluable emotional support and practical advice for navigating daily challenges.

Pregnancy and fertility

For individuals with Dravet syndrome, pregnancy is rarely a consideration due to the severe intellectual disability associated with the condition. However, for family members and future family planning, genetic counseling is important.

Women taking antiepileptic drugs who are planning pregnancy should consult with their healthcare team about medication safety, as some drugs may increase the risk of birth defects. For families with an affected child considering future pregnancies, genetic counseling can provide information about recurrence risks and available reproductive options.

Children

Dravet syndrome exclusively affects children, with onset in infancy and lifelong impact. Educational planning is crucial, with most children requiring specialized educational settings with seizure management capabilities. Individualized education programs (IEPs) should address communication needs, mobility issues, and behavioral challenges.

Family support is essential, as caring for a child with Dravet syndrome places enormous physical, emotional, and financial stress on families. Respite care, support groups, and connecting with patient organizations can provide vital assistance. Siblings may need additional support to understand and cope with their family situation.

When to see a doctor

Emergency care is needed immediately for: Any seizure lasting more than 5 minutes, difficulty breathing during or after seizures, injury during seizures, or clusters of seizures occurring more frequently than usual.

Urgent medical attention is required for: Any seizure in a child under 1 year of age, seizures accompanied by fever, significant changes in seizure pattern or frequency, or new concerning symptoms.

Routine follow-up should address: Medication adjustments, developmental assessments, and coordination of care with multiple specialists including neurology, genetics, and developmental pediatrics.

Regional context

Limited data exists on Dravet syndrome prevalence specifically in the Caucasus region (Georgia, Armenia, Azerbaijan) or Eastern Mediterranean countries. The condition appears to affect all ethnic groups and geographic regions equally. Healthcare access and genetic testing availability may vary significantly across these regions, potentially affecting diagnosis rates and treatment options.

We invite healthcare professionals and researchers from these regions to contribute data and insights about Dravet syndrome prevalence, diagnostic challenges, and treatment accessibility to enhance understanding of the condition’s regional impact.

Research and clinical trials

Current research focuses on developing new treatments targeting the underlying sodium channel dysfunction, gene therapy approaches, and improved seizure management strategies. Several promising therapies are in clinical development, including new antiepileptic drugs specifically designed for SCN1A-related epilepsies.

Gene therapy research is exploring ways to restore normal SCN1A function, though these approaches are still in early experimental stages. Antisense oligonucleotide therapies and other precision medicine approaches are being investigated. Researchers are also studying biomarkers to better predict treatment response and disease progression.

Families interested in clinical trials can search for current studies at ClinicalTrials.gov using the search term “Dravet syndrome.” Patient registries are also collecting important data about disease progression and treatment outcomes to inform future research directions.

Frequently asked questions

Will my child with Dravet syndrome ever be able to live independently?

Unfortunately, most individuals with Dravet syndrome require lifelong supervised care due to severe intellectual disability, ongoing seizures, and safety concerns. However, with appropriate support and therapies, many can participate in meaningful activities and maintain quality of life within their capabilities.

Can the ketogenic diet cure Dravet syndrome?

The ketogenic diet cannot cure Dravet syndrome, but it may help reduce seizure frequency in some patients. The diet requires careful medical supervision and may be used alongside medications as part of a comprehensive treatment plan.

Is Dravet syndrome hereditary, and what are the chances of having another affected child?

Most cases (over 95%) are caused by de novo mutations, meaning they occur spontaneously and are not inherited from parents. The recurrence risk for future pregnancies is generally low (less than 5%), but genetic counseling is recommended for accurate risk assessment.

Why are some seizure medications forbidden in Dravet syndrome?

Sodium channel blocking medications like lamotrigine and carbamazepine can actually worsen seizures in Dravet syndrome because they further impair the already dysfunctional sodium channels caused by SCN1A mutations. This can lead to increased seizure frequency and severity.

What should I do if my child has a prolonged seizure?

For seizures lasting more than 5 minutes, administer prescribed emergency medication (such as rectal diazepam or nasal midazolam) if available and call emergency services immediately. Position the child safely, time the seizure, and never put anything in their mouth during the seizure.

Support and resources

Dravet Syndrome Foundation: dravetfoundation.org – Primary patient advocacy organization providing family support, research funding, and educational resources.

Orphanet: orpha.net – Comprehensive rare disease database with detailed medical information.

National Organization for Rare Disorders (NORD): rarediseases.org – Patient advocacy and support for rare disease communities.

EURORDIS: eurordis.org – European alliance of rare disease organizations.

International League Against Epilepsy: ilae.org – Professional organization with patient resources for epilepsy conditions.

Related conditions

Lennox-Gastaut syndrome, SCN2A-related disorders, SCN8A epileptic encephalopathy, PCDH19 clustering epilepsy, Developmental epileptic encephalopathies

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.